Next-generation sequencing (NGS) has been widely used in research for the past decade or more; however, its translation into the clinic has taken more time. Here, Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the limits to widespread NGS implementation and how we can overcome them. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Overcoming the limits to widespread NGS implementation
